2026-05-06 · 2026-05 / week-1
DHY Is Pricing the Rights Overhang, but the NAV Math Is Smaller
DHY Is Pricing the Rights Overhang, but the NAV Math Is Smaller
Opportunity Ranking
| Rank | Idea | Discovery Lane | Why It May Be Best Now | Evidence Freshness | Catalyst Window | Asymmetry | Main Reason to Reject |
|---|---|---|---|---|---|---|---|
| 1 | Credit Suisse High Yield Credit Fund rights overhang | closed-end fund rights / high-yield credit | DHY's common shares trade near the estimated rights subscription price even though the fund's own prospectus example frames NAV dilution at only 1.10% if the primary subscription is fully exercised. | UBS fund page showed NAV of $2.02 as of May 5, 2026; Finviz showed last close of $1.76 on May 5 at 4:00 p.m. ET; SEC prospectus supplement was filed April 21. | Rights submitted to the subscription agent for sale are due May 7; rights are expected to stop trading May 13; the offer expires May 14. | Tight but defined: a $1.76 common price versus $2.02 NAV leaves room for discount normalization if the rights event clears without a credit selloff. | The trade is small, source quotes disagree, and a real high-yield credit drawdown would swamp the rights mechanics. |
| 2 | MFS Investment Grade Municipal Trust 50% tender | closed-end fund tender / municipal fund reorganization | CXH has an open tender for up to 50% of shares at 99% of NAV tied to a broader MFS municipal fund reorganization. | MFS commencement release dated April 13, 2026; CXH market snapshot at $8.345 on May 5, 2026 at 23:15 UTC. | Tender expires May 12, 2026, unless extended. | Potentially high for already-held shares because half the fund can be taken out near NAV. | Pro-ration, stale public NAV data, tax-exempt rate exposure, and low volume make the new-entry edge harder to underwrite. |
| 3 | First Trust Senior Floating Rate Income Fund II ETF conversion vote | closed-end fund conversion / senior-loan discount | FCT shareholders vote June 9 on a CEF-to-ETF reorganization, which should structurally attack the discount if approved. | Proxy/prospectus dated April 17, 2026; FCT market snapshot at $9.78 on May 5, 2026 at 23:15 UTC; proxy disclosed $9.90 NAV and $9.64 price on March 31. | June 9, 2026 shareholder meeting. | High probability but narrow because the discount has already tightened to a low-single-digit process spread. | Better process certainty than DHY, but less payoff and a later catalyst. |
Selected opportunity: Credit Suisse High Yield Credit Fund (DHY) common shares around the rights-offering expiration.
Why this one now: The common share is trading as if the rights overhang is the main fact. The next eight calendar days decide whether that overhang is real supply, stale quoted confusion, or a small mechanical event that the market has over-discounted.
What should surprise the reader: The issue is not whether a below-NAV rights offering is dilutive. It is. The surprise is that DHY's common price has moved close to the fund's own estimated subscription price while the prospectus example puts full-primary-subscription NAV dilution at only 1.10%.
The Setup
Credit Suisse High Yield Credit Fund is running a transferable 1-for-3 rights offering. One right was issued for each common share held on the record date, and three rights allow the holder to subscribe for one new common share. The rights trade on NYSE American under DHY RT; the fund says the rights are expected to cease trading on May 13, 2026, one trading day before the offer expires at 5:00 p.m. Eastern Time on May 14. UBS rights-offering announcement
The subscription price is formulaic. It will be the higher of 92.5% of the average market price on the expiration date and the four preceding trading days, or 86.0% of NAV on the expiration date. At the current live inputs used for this draft, $1.76 common price and $2.02 NAV, the NAV floor controls: 86.0% of $2.02 is $1.737. SEC prospectus supplement
This matters because the common share is already near that floor. Finviz showed DHY's last close at $1.76 on May 5, 2026 at 4:00 p.m. ET, with 1.01 million shares traded, 103.61 million shares outstanding, 27.82% institutional ownership, 1.15% short float, and an RSI of 33.87. Finviz DHY quote
The NAV anchor is separate. UBS's fund page showed NAV of $2.02, net assets of $209.5 million, and 103.61 million shares outstanding as of May 5, 2026. The same UBS table also showed a daily closing price of $1.89 and a 5.97% discount. That conflicts with the live common-share quote sources used here. This is not a cosmetic discrepancy. If a trader's executable screen shows $1.89 rather than $1.76, the thesis should be rejected at that screen. UBS DHY fund page
The Mispricing
The market appears to be pricing the rights offering as a large, messy dilution event. The better version is narrower: the trade is a rights-overhang cleanup, not a bet that DHY's high-yield portfolio suddenly deserves a materially tighter credit valuation.
At $1.76, DHY trades at a 12.9% discount to the $2.02 UBS NAV reference. Before the rights offering, the fund's March 27 prospectus table showed NAV of $1.99, market price of $1.84, and a 7.54% discount. The common has therefore moved from a mid-single to high-single discount framework into a low-teens discount framework while the key event is mechanical and dated. SEC prospectus supplement
The variant perception is that the rights have very little intrinsic value at the current common price. With a $1.737 implied floor subscription price and a $1.76 common quote, the basic rights value is only about half a cent per right under the standard 1-for-3 formula: (market price - subscription price) / 4. If the right is nearly exhausted, the common-share discount may be carrying more event fear than residual economics.
Price
Current market setup, using the sources above:
| Reference | Level | Timestamp / Date | Source |
|---|---|---|---|
| DHY common share last close | $1.76 | May 5, 2026, 4:00 p.m. ET | Finviz |
| DHY NAV | $2.02 | Last update May 5, 2026 | UBS fund page |
| Implied discount using $1.76 / $2.02 | -12.9% | Calculated May 6, 2026 | Finviz + UBS |
| UBS daily closing price reference | $1.89 | Last update May 5, 2026 | UBS fund page |
| UBS stated premium / discount | -5.97% | Last update May 5, 2026 | UBS fund page |
| Estimated current 86% NAV floor | $1.737 | Calculated from $2.02 NAV | UBS + prospectus formula |
| Prospectus estimated subscription price | $1.75 | Based on April 15 NAV example | SEC prospectus supplement |
The table carries the core execution warning. The article's upside case exists only if the $1.76 common-share quote is the relevant executable price. If the market is already clearing near $1.89, the discount has already normalized and the trade becomes stale.
Positioning
The positioning evidence is partial but useful. DHY is a micro-cap closed-end fund with 103.61 million shares outstanding and 1.01 million shares traded on May 5, above Finviz's 729,050 average volume. Short interest is not the point; Finviz showed short float at only 1.15%. The pressure is rights-event supply and investor friction, not a crowded borrow trade. Finviz DHY quote
The rights structure creates a holder split. Record-date shareholders who fully exercise their rights may seek over-subscription shares. Holders who buy rights in the secondary market may not participate in the over-subscription privilege. Record-date shareholders who sell rights give up that privilege. The last day to submit rights to the subscription agent for sale is May 7, and rights are expected to trade until May 13. SEC prospectus supplement
That is the positioning tension. Natural income-fund holders have to decide whether to add capital to a leveraged high-yield CEF below NAV, sell rights that may have minimal value, or ignore the event and accept dilution. Secondary-rights buyers do not get the same over-subscription economics. The common can therefore trade heavy even when the arithmetic damage is smaller than the price action implies.
What is missing: there is no reliable public read on rights trading depth, dealer inventory, broker-level exercise intentions, or the percentage of record-date holders likely to over-subscribe. The article treats the flow claim as an inference from the rights terms and common-share tape, not as proven order-book data.
Catalyst
The catalyst path is tight:
| Date | Event | Why It Matters |
|---|---|---|
| May 7, 2026 | Deadline for rights submitted to the subscription agent for sale | First cleanup point for holders who do not want to exercise directly. |
| May 13, 2026 | Expected final trading day for DHY RT |
The transferable-rights overhang should stop being a live market quote. |
| May 14, 2026 | Rights offering expiration at 5:00 p.m. Eastern Time | Final subscription price, exercise demand, and oversubscription pressure become knowable. |
| Up to five days after expiration | Board may eliminate over-subscription privilege | Residual uncertainty for record-date holders seeking extra shares. |
| May 22, 2026 | Monthly distribution payment date for May 4 record holders | New rights shares are not entitled to the April 23 or May 22 distributions. |
The closing mechanism is not a conference call. It is the removal of an event that has been forcing common-share holders to price dilution, rights value, oversubscription access, and quote inconsistency at the same time.
Payoff Map
The cleanest expression is the common stock, sized as a short-duration process trade. Options do not fit: Finviz flags DHY as having no listed options, and leverage is unnecessary for a low-priced CEF with event-date risk.
One possible expression is to own DHY common only if the executable price is near the $1.76 quote and the investor is willing to exit if the post-expiration discount does not begin to narrow. The rights themselves are inferior for most secondary buyers because secondary-market rights do not carry over-subscription privilege, and the current intrinsic value is minimal if the NAV floor controls.
The alternative expression, buying DHY RT, is worse unless a buyer has a specific rights-pricing edge. At $1.76 common and roughly $1.74 subscription floor, the right is mathematically small. The common gives cleaner exposure to discount normalization after the event.
Price Target and Probability Map
| Scenario | Probability | Target / Level | Return / Payoff | Time Horizon | Conditions Required | Evidence Quality |
|---|---|---|---|---|---|---|
| Top Case | 25% | $1.90 DHY common | +8.0% from $1.76 | May 15 to June 30, 2026 | Rights expire, quote-source discrepancy resolves toward UBS's tighter-discount reference, and high-yield credit does not sell off. | Medium |
| Base Case | 45% | $1.84 DHY common | +4.5% from $1.76 | May 15 to June 30, 2026 | Rights pressure clears and DHY returns to roughly a 9% discount on a $2.02 NAV reference after modest offering dilution. | Medium |
| Bottom Case | 30% | $1.68 DHY common | -4.5% from $1.76 | Immediate to June 30, 2026 | Subscription demand is weak, NAV falls, high-yield credit widens, or the market continues to apply a mid-teens discount after the event. | Medium |
| Invalidation / Stop Condition | n/a | Below $1.68, or still below $1.75 after May 17 without a high-yield credit shock | n/a | Immediate to three trading days after expiration | The rights event is not the source of the discount, or the market is correctly repricing the underlying credit and leverage risk. | High |
Probability-weighted expected value: $1.807, or approximately +2.7% versus $1.76. This is a process-spread EV, not a fundamental target.
Current market price / level: DHY common at $1.76 as of the May 5, 2026 close on Finviz and the live market-data snapshot used for this draft; UBS NAV at $2.02 as of May 5, 2026.
Timestamp: Draft prepared May 6, 2026 at 10:49 Asia/Ho_Chi_Minh, using May 5 U.S. closing data.
Primary instrument: DHY common shares.
Alternative expressions considered: DHY rights, no trade until after May 14, or a broader high-yield ETF hedge. The rights are rejected for most secondary buyers because over-subscription privilege does not travel with secondary-market rights. A broad ETF hedge is imprecise because the event risk is DHY-specific.
Confidence: Medium-low. The event is dated and the arithmetic is auditable, but the quote conflict and credit exposure keep this below high conviction.
What Would Prove This Wrong
The thesis fails first if executable DHY common is not actually near $1.76. If the tradable price is closer to UBS's $1.89 daily closing reference, the discount has already tightened and the article's payoff map is obsolete.
It also fails if NAV falls below $1.95 before the final subscription price is set. A below-NAV rights offering is not the only risk here. DHY owns below-investment-grade credit, uses leverage, and the prospectus says leverage expenses are borne by common shareholders. If credit weakens, the discount can stay wide for the right reason. SEC prospectus supplement
Finally, it fails if the post-expiration common price does not improve after rights stop trading. A mechanical overhang should start to clear quickly. If it does not, the market is probably not just selling the rights event.
Risk Audit
Strongest counterargument: The market may be correct to widen DHY's discount. A leveraged high-yield CEF issuing below-NAV stock during an uncertain credit window deserves a larger discount than a clean high-yield ETF.
Most fragile assumption: The setup assumes the $1.76 common-share quote is the executable reference and that the rights event is depressing price more than underlying credit risk.
What the market may already know: Everyone can read the May 14 expiration date, the 1-for-3 structure, the subscription formula, and the dilution example.
What could make the trade lose money even if the thesis is directionally right: NAV can fall, spreads can widen, rights exercise can disappoint, or the discount can remain wide because investors dislike the adviser economics and leverage rather than the offering mechanics.
Liquidity / execution risks: DHY traded about 1.01 million shares on May 5, but it is still a micro-cap CEF. Limit orders matter. The quote-source discrepancy between Finviz and UBS is a live execution risk.
Leverage risks: The fund can use leverage up to 33 1/3% of total assets under its prospectus. Leverage can help income when credit is stable and hurt NAV when credit sells off.
Information reliability risks: The rights terms and NAV data come from official UBS and SEC sources. The current common quote is sourced from market-data screens that conflict with UBS's daily closing table.
Invalidation trigger: A confirmed executable price near $1.89, NAV below $1.95 before expiration, or DHY still below $1.75 three trading days after the rights expire without a credit-market shock.
Publish / revise / reject recommendation: Publish as a medium-low-confidence short-duration event note, not as a high-conviction deep dive. The edge is specific, but the sizing should reflect the quote conflict.
Bottom Line
DHY is not a clean cheap-credit story. It is a dated rights-overhang setup where the common appears to have moved close to the subscription floor while the prospectus example frames full-primary-subscription NAV dilution at only 1.10%. The best trade strategy is a stock-based process trade in DHY common near $1.76, with no leverage, no need to buy secondary-market rights, and a hard rejection if the executable price is closer to $1.89 or if the post-May 14 discount refuses to narrow.
Sources
| Source | Use |
|---|---|
| UBS rights-offering announcement, April 14, 2026 | Subscription formula, May 14 expiration, May 13 expected final rights trading day, fund investment policy. |
| SEC prospectus supplement, April 21, 2026 | 1-for-3 rights structure, estimated $1.75 subscription price, dilution example, proceeds, expenses, over-subscription rules, leverage risk. |
| UBS DHY fund page | NAV, net assets, shares outstanding, official daily-price table, and the conflicting $1.89 daily closing reference. |
| Finviz DHY quote | May 5 common-share close, volume, shares outstanding, short float, institutional ownership, RSI, and average volume. |
| MFS closed-end fund releases | Candidate screen for CXH tender-offer terms and timing. |
| First Trust FCT proxy/prospectus | Candidate screen for FCT ETF-conversion vote, March 31 NAV, and meeting date. |